Articles tagged "Malignancy"

2017 American Transplant Congress
BK Polyoma Virus and Malignancy: Cause or Co-Incidence?
R. Prashar, A. Shah, D. Stewart, S. Williamson, A. Patel.
Henry Ford Transplant Institute, Detroit, MI
BackgroundThe WHO agency for cancer research has classified BKV as "possibly carcinogenic".The etiological role of BKV in human cancer, however,remains controversial.We present 5 cases of…
2017 American Transplant Congress
Nonmelanoma Skin Cancer Rates Are Not Affected by Chronic HIV(+) or HCV(+) Infection in Organ Transplant Recipients.
K. Nadhan, E. Usedom, S. Shipman, A. Doyle, G. Malat, E. Buchanan, C. Chung.
Dermatology, Drexel, Philadelphia
Purpose: HIV and HCV are two immune dysregulatory processes that may exacerbate the risk of nonmelanoma skin cancer (NMSC) in organ transplant recipients (OTR), a…
2017 American Transplant Congress
High-Risk Human Papillomavirus Associated with Genital Squamous Cell Carcinoma in Nonwhite Organ Transplant Recipients.
K. Nadhan,¹ M. Larijani,¹ L. Ogrich,¹ C. Shaver,¹ A. Doyle,² C. Chung.¹
¹Dermatology, Drexel University, Philadelphia, PA; ²Internal Medicine, University of Virginia, Charlottesville, VA
Purpose: Squamous cell carcinoma (SCC) confers significantly increased mortality in both solid organ transplant recipients (OTR) and the immunocompetent nonwhite population. In the latter, a…
2017 American Transplant Congress
Prevalence of Cutaneous Disease in Solid Organ Transplant Recipients: A 5-Year Study from a Medical -Surgical Transplant Dermatology Center.
R. Allawh, A. Weiffenbach, K. Nadhan, M. Abdelmalek, C. Cusack, C. Chung.
Dermatology, Drexel University College of Medicine, Philadelphia, PA
Background: Solid organ transplant recipients (OTR) on chronic immunosuppression exhibit heightened risk of developing a myriad of cutaneous manifestations compared to non-transplant patients, including cutaneous…
2016 American Transplant Congress
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.
S. Chadban,¹ H. Pilmore,² G. Russ,³ J. Kanellis,⁴ S. Campbell,⁵ P. O'Connell,⁶ W. Lim,⁷ M. Lutherborrow,⁸ N. Kurstjens,⁸ R. Walker.⁹
¹Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Auckland Renal Transplant, Auckland City Hospital, Auckland, New Zealand; ³Central Northern Adelaide Ranel and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; ⁴Renal Medicine, Monash Medical Centre, Melbourne, Australia; ⁵University of Queensland, Princess Alexandra Hospital, Queensland, Australia; ⁶Renal Medicine, Westmead Hospital, Sydney, Australia; ⁷WA Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Australia; ⁸Novartis Pharmaceuticals, Sydney, Australia; ⁹Renal Medicine, Alfred Hospital, Melbourne, Australia.
A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…
2016 American Transplant Congress
Outcomes of Solid Organ Transplant Recipients with Pre-Existing Malignancies.
S. Acuna,^1,2,3 R. Sutradhar,^1,2 J. Kim,^1,2,4 N. Baxter.^1,2,3
¹Institute of Health Policy, Management and Education, University of Toronto, Toronto, ON, Canada; ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; ³Department of Surgery, St. Michael's Hospital, Toronto, ON, Canada; ⁴Department of Medicine, University Health Network, Toronto, ON, Canada.
Background: Pre-transplant malignancy (PTM) is considered a relative contraindication for transplantation due to the heightened risk of cancer recurrence associated with immunosuppression. However, little has…
2016 American Transplant Congress
Malignancies Contribute to Presensitization with Alloreactive T-Cells in Kidney Transplant Recipients.
T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
¹Nephrology and Internal Intensive Care, Charite Campus Virchow Clinic, Berlin, Germany; ²Berlin-Brandenburg Center for Regenerative Therapies, Charite Campus Virchow Clinic, Berlin, Germany.
Alloreactive T-cells have been suggested to impact allograft outcome due to a higher incidence of acute rejection in the initial period after kidney transplantation. Knowledge…
2016 American Transplant Congress
Does Post-Transplant Adherence Come at a Cost?
K. Yadav, T. Nevins, D. Vock, W. Thomas, W. Robiner, A. Matas.
University of Minnesota, Minneapolis, MN.
Background: It is well documented that organ transplant (tx)recipients have an increased incidence of cancer including virus associated cancers like lymphoma. Our objective was to…
2016 American Transplant Congress
Selection of Patients with Solitary Lesion of Hepatocellular Cancer for Liver Transplantation.
M. Grąt,¹ J. Stypułkowski,¹ W. Patkowski,¹ K. Wronka,¹ M. Wasilewicz,² K. Grąt,³ L. Masior,¹ M. Krasnodębski,¹ Z. Lewandowski,⁴ M. Krawczyk.¹
¹Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland; ²Department of General, Transplant and Liver Surgery, Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland; ³Second Department of Clinical Radiology, Medical University of Warsaw, Warsaw, Poland; ⁴Department of Epidemiology, Medical University of Warsaw, Warsaw, Poland.
Milan criteria are considered as benchmark for selection of patients with hepatocellular cancer (HCC) for liver transplantation. The aim of this study was to evaluate…
2016 American Transplant Congress
Chemoprevention of Cutaneous Squamous Cell Carcinoma in Renal Transplant Recipients: A Case-Controlled Analysis.
R. Anand, R. Hung, S. Frame, K. Bramham, M. Wain, A. Cronin.
Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.
Organ transplant recipients are up to 200 times more likely to develop cutaneous squamous cell carcinoma (SCC) than age-matched general populations. Systemic retinoids, such as…